1304TiPA randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
Weber, J, Long, G V, Haanen, J B, Arance, A, Dummer, R, Nathan, P, Ribas, A, Ascierto, P A, Robert, C, Gasal, E, D’Amelio, A, Bettinger, S, Boran, A D, Schadendorf, DVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy289.060
Date:
October, 2018
File:
PDF, 91 KB
english, 2018